1od9: Difference between revisions
No edit summary |
No edit summary |
||
| Line 29: | Line 29: | ||
[[Category: siglec]] | [[Category: siglec]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 15:50:22 2007'' | ||
Revision as of 16:45, 30 October 2007
|
N-TERMINAL OF SIALOADHESIN IN COMPLEX WITH ME-A-9-N-BENZOYL-AMINO-9-DEOXY-NEU5AC (BENZ COMPOUND)
OverviewOverview
The Siglec family of receptors mediates cell surface interactions through, recognition of sialylated glycoconjugates. The crystal structure of the, N-terminal immunoglobulin-like domain of the Siglec sialoadhesin (SnD1) in, complex with 2,3-sialyllactose has informed the design of sialic acid, analogs (sialosides) that bind Siglecs with significantly enhanced, affinities and specificities. Binding assays against sialoadhesin (Sn;, Siglec-1), CD22 (Siglec-2), and MAG (Siglec-4) show a 10- to 300-fold, reduction in IC(50) values (relative to methyl-alpha-Neu5Ac) for three, sialosides bearing aromatic group modifications of the glycerol side, chain: Me-alpha-9-N-benzoyl-amino-9-deoxy-Neu5Ac (BENZ), Me-alpha-9-N-(naphthyl-2-carbonyl)-amino-9-deoxy-Neu5Ac (NAP), and, ... [(full description)]
About this StructureAbout this Structure
1OD9 is a [Single protein] structure of sequence from [Mus musculus] with SO4 and BND as [ligands]. Structure known Active Site: BND. Full crystallographic information is available from [OCA].
ReferenceReference
Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin., Zaccai NR, Maenaka K, Maenaka T, Crocker PR, Brossmer R, Kelm S, Jones EY, Structure. 2003 May;11(5):557-67. PMID:12737821
Page seeded by OCA on Tue Oct 30 15:50:22 2007